Zobrazeno 1 - 10
of 724
pro vyhledávání: '"Egbert F. Smit"'
Autor:
Franziska Böttger, Teodora Radonic, Idris Bahce, Kim Monkhorst, Sander R. Piersma, Thang V. Pham, Anne‐Marie C. Dingemans, Lisa M. Hillen, Mariacarmela Santarpia, Elisa Giovannetti, Egbert F. Smit, Sjaak A. Burgers, Connie R. Jimenez
Publikováno v:
Molecular Oncology, Vol 18, Iss 6, Pp 1417-1436 (2024)
The majority of patients with resected stage II‐IIIA non‐small cell lung cancer (NSCLC) are treated with platinum‐based adjuvant chemotherapy (ACT) in a one‐size‐fits‐all approach. However, a significant number of patients do not derive c
Externí odkaz:
https://doaj.org/article/59cc7532a44a481fb7f9c9573d143ffd
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV60
Externí odkaz:
https://doaj.org/article/5d4d7a8e57754e16812b1b989f4ffe66
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100875- (2024)
Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD
Externí odkaz:
https://doaj.org/article/fc99db69ccab44d8b32b3ad075d188c3
Autor:
Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S. H. Ng, David Planchard, Sanjay Popat, Julia Rotow, Egbert F. Smit, Ross Soo, Masahiro Tsuboi, Fan Yang, Brendon Stiles, Christian Grohe, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
IntroductionOsimertinib is recommended by major guidelines for use in the adjuvant setting in patients with EGFR mutation-positive NSCLC following the significant improvement in disease-free survival observed in the Phase III ADAURA trials. Due to li
Externí odkaz:
https://doaj.org/article/16b99c860cb44565b5aca42740985756
Autor:
Frank J. Borm, Jasper Smit, Joyce Bakker, Maurits Wondergem, Egbert F. Smit, Adrianus J. de Langen, Tanja D. de Gruijl
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTBetter biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission to
Externí odkaz:
https://doaj.org/article/b3bac891f09a4fdfb2e410416d7ae4df
Autor:
Hanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N. Storm, Sylvia A. van Laar, Johanneke EA Portielje, Henk Codrington, Dieuwke Luijten, Pepijn Brocken, Egbert F. Smit, Loes E. Visser
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background This study was designed to investigate the impact of age on the effectiveness and immune-related adverse events (irAEs) of programmed death-(ligand)1 [PD-(L)1] inhibitors in patients with non-small cell lung cancer (NSCLC) using a
Externí odkaz:
https://doaj.org/article/6e2c3adabad54791a0cd2e967e1b62e7
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101955- (2023)
Summary: Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimert
Externí odkaz:
https://doaj.org/article/3a9954ccf1454c0c889fa14273839a4e
Autor:
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma con
Externí odkaz:
https://doaj.org/article/4457ff0cdd7b4bd9aa0922759784c7a7
Autor:
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether i
Externí odkaz:
https://doaj.org/article/7a4d1f9500d043fca5a9dd6a08afeeba